These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 15199354

  • 1. Preventing recurrent events long term after coronary artery bypass graft: suboptimal use of medications in a population study.
    Bradshaw PJ, Jamrozik K, Gilfillan I, Thompson PL.
    Am Heart J; 2004 Jun; 147(6):1047-53. PubMed ID: 15199354
    [Abstract] [Full Text] [Related]

  • 2. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.
    Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudtson ML, APPROACH Investigators.
    J Am Coll Cardiol; 2004 Oct 19; 44(8):1587-92. PubMed ID: 15489090
    [Abstract] [Full Text] [Related]

  • 3. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.
    Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, Kouchoukos NT, Harrington RA, Gennevois D, Gibson CM, Califf RM, Ferguson TB, Peterson ED, PREVENT IV Investigators.
    Ann Thorac Surg; 2007 Mar 19; 83(3):993-1001. PubMed ID: 17307447
    [Abstract] [Full Text] [Related]

  • 4. Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention?
    Fox DJ, Kibiro M, Eichhöfer J, Curzen NP.
    Postgrad Med J; 2005 Jun 19; 81(956):401-3. PubMed ID: 15937208
    [Abstract] [Full Text] [Related]

  • 5. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality.
    Henke PK, Blackburn S, Proctor MC, Stevens J, Mukherjee D, Rajagopalin S, Upchurch GR, Stanley JC, Eagle KA.
    J Vasc Surg; 2004 Feb 19; 39(2):357-65. PubMed ID: 14743136
    [Abstract] [Full Text] [Related]

  • 6. Elderly patients undergoing major vascular surgery: risk factors and medication associated with risk reduction.
    Feringa HH, Bax JJ, Karagiannis SE, Noordzij P, van Domburg R, Klein J, Poldermans D.
    Arch Gerontol Geriatr; 2009 Feb 19; 48(1):116-20. PubMed ID: 18177954
    [Abstract] [Full Text] [Related]

  • 7. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS, Bajorek BV.
    J Clin Pharm Ther; 2008 Dec 19; 33(6):591-601. PubMed ID: 19138236
    [Abstract] [Full Text] [Related]

  • 8. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study.
    Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD, Granger CB, Erickson S, White K, Steg PG.
    Am J Med; 2004 Jul 15; 117(2):73-81. PubMed ID: 15234641
    [Abstract] [Full Text] [Related]

  • 9. Invasive vs non-invasive treatment in acute coronary syndromes and prior bypass surgery.
    Gurfinkel EP, Perez de la Hoz R, Brito VM, Duronto E, Dabbous OH, Gore JM, Anderson FA, GRACE Investigators.
    Int J Cardiol; 2007 Jun 25; 119(1):65-72. PubMed ID: 17045681
    [Abstract] [Full Text] [Related]

  • 10. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
    Corp EV, Antoniou S, Wright PG, Khachi H, Vercaeren S, Wald DS.
    QJM; 2009 Dec 25; 102(12):843-9. PubMed ID: 19828644
    [Abstract] [Full Text] [Related]

  • 11. Predictors of long-term use of evidence-based therapies after non-ST-segment elevation acute coronary syndrome. The S-Témoin survey.
    Danchin N, Diévart F, Thébaut JF, Grenier O, Mihci E, Herrmann MA, Ferrières J.
    Int J Cardiol; 2009 Mar 20; 133(1):32-40. PubMed ID: 18375000
    [Abstract] [Full Text] [Related]

  • 12. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
    Reiner Z, Mihatov S, Milicić D, Bergovec M, Planinc D, TASPIC-CRO Study Group Investigators.
    Eur J Cardiovasc Prev Rehabil; 2006 Aug 20; 13(4):646-54. PubMed ID: 16874158
    [Abstract] [Full Text] [Related]

  • 13. Should all patients be treated with an angiotensin-converting enzyme inhibitor after coronary artery bypass graft surgery? The impact of angiotensin-converting enzyme inhibitors, statins, and β-blockers after coronary artery bypass graft surgery.
    Kalavrouziotis D, Buth KJ, Cox JL, Baskett RJ.
    Am Heart J; 2011 Nov 20; 162(5):836-43. PubMed ID: 22093199
    [Abstract] [Full Text] [Related]

  • 14. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.
    Anselmino M, Malmberg K, Ohrvik J, Rydén L, Euro Heart Survey Investigators.
    Eur J Cardiovasc Prev Rehabil; 2008 Apr 20; 15(2):216-23. PubMed ID: 18391651
    [Abstract] [Full Text] [Related]

  • 15. Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population.
    Mehta JL, Bursac Z, Hauer-Jensen M, Fort C, Fink LM.
    Am J Cardiol; 2006 Oct 01; 98(7):923-8. PubMed ID: 16996875
    [Abstract] [Full Text] [Related]

  • 16. [Evaluation of hospitalization period and five-year follow-up of patients admitted with acute coronary syndrome following coronary artery bypass graft surgery].
    Can LH, Kayıkçıoğlu M, Yavuzgil O, Kültürsay H, Soydan I.
    Turk Kardiyol Dern Ars; 2010 Sep 01; 38(6):387-92. PubMed ID: 21200116
    [Abstract] [Full Text] [Related]

  • 17. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.
    Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, Oliveira SA, Ramires JA.
    Circulation; 2007 Mar 06; 115(9):1082-9. PubMed ID: 17339566
    [Abstract] [Full Text] [Related]

  • 18. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
    Chodick G, Shalev V, Gerber Y, Heymann AD, Silber H, Simah V, Kokia E.
    Clin Ther; 2008 Nov 06; 30(11):2167-79. PubMed ID: 19108805
    [Abstract] [Full Text] [Related]

  • 19. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.
    Bi Y, Gao R, Patel A, Su S, Gao W, Hu D, Huang D, Kong L, Qi W, Wu Y, Yang Y, Turnbull F, CPACS Investigators.
    Am Heart J; 2009 Mar 06; 157(3):509-516.e1. PubMed ID: 19249422
    [Abstract] [Full Text] [Related]

  • 20. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study.
    Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM.
    Can J Cardiol; 2005 May 01; 21(6):485-8. PubMed ID: 15917876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.